Genmab — December 2018
-
Genmab ser umiddelbart stærk ud her i åbningen.
-
-
http://ir.bellicum.com/static-files/3ccea6d9-5cfd-45b6-be9a-f9f32a089d6d Judith Klimovsky board seat at Bellicum Pharmaceuticals, they do stem cell transplant, TCR and CAR T cell therapies http://www.bellicum.com/
-
Who read Thomas Bowers update this week? i understand he refers to this ash abstract https://ash.confex.com/ash/2018/webprogram/Paper110323.html and adds that Plessner says that this could imply that Dara should be used in all lines of therapy?
-
Ikke mindst hensynet til åbningsider: Although limited evidence is available to suggest that the overall incidence of infusion reactions is reduced, the chair time in the chemotherapy outpatient unit can be scheduled more conveniently because the need to arrange for an urgent overnight stay for a patient in whom the first dose runs into the evening is avoided. http://ascopubs.org/doi/full/10.1200/JOP.18.00377
-
Måske milestone..:-)
-
Ku´godt se ud til at vi ender i +...stærkt!
-
Både Genmab og Novo er i plus.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind